Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.
Also called NCT04023227
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 922 participants
- Sponsor
- Registry
-
NCT04023227
-
- Other papers using this trial's data
- Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Brazil, Colombia, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT04023227. Randomized; single masking; primary purpose treatment. Start 2019-12-10 (actual); primary completion 2025-03-16 (actual). Results posted on 2026-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- Acronym
- PARACHUTE-HF
- Condition
- Chagas Disease
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril/valsartan
- Intervention (Drug)
- Enalapril
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04023227- Content hash
c3a3515b8e54bd61efbc7d3c96246ebae3140b25589406b2c75a6239a2f631a6